Condition: Malignant Brain Tumors · Sponsor: Haisco Pharmaceutical Group Co., Ltd.
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Xuanwu Hospital Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China | Beijing, Beijing Municipality, China | Recruiting |
| The first affiliated hospital of fujian medical university | Fuzhou, Fujian, China | Recruiting |
| Zhujiang Hospital of Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
| The Third Bethune Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| Fudan University Affiliated Huashan Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07158710